Influence of oncostatin M and leukemia inhibitor factor on sarcopenia in individuals with cancer and malnutrition

The average age was 66.5±15.5 years. The gender distribution was 16 females (48.5%) and 17 males (51.5%). Sixteen patients (48.5%) were diagnosed with sarcopenia. Patients with sarcopenia showed worse values: phase angle (-0.4±0.1°; p=0.01), reactance (-4.9±1.8Ω; p=0.03), SMM (-2.0±0.3kg; p=0.03), aSMM (-1.6±0.2kg; p=0.03), aSMMI (-0.6±0.2kg/m²; p=0.02), muscle area RF (-0.7±0.2cm²; p=0.04), Y-axis RF (-0.4±0.1cm; p=0.03), muscle strength (-8.1±1.5kg; p=0.01) and albumin levels (-0.3±0.1g/dl; p=0.03). Circulating levels of OSM and LIF were elevated in patients with sarcopenia, with values of 10.6±1.3pg/ml (p=0.01) and 6.4±2.3pg/ml (p=0.02), respectively. Logistic regression analysis indicated a significant OR (odds ratio) of sarcopenia associated with elevated median levels of OSM (OR=3.6, 95% CI=1.4-9.9; p=0.01) and LIF-1 (OR=3.3, 95% CI=1.3-10.1; p=0.01) CONCLUSION: High levels of serum OSM and LIF-1 were closely associated with sarcopenia in patients with cancer and DRM.